|
1
|
Buckner JC: Factors influencing survival
in high-grade gliomas. Semin Oncol. 30:10–14. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Curran WJ Jr, Scott CB, Horton J, Nelson
JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO,
Krisch RE, et al: Recursive partitioning analysis of prognostic
factors in three Radiation Therapy Oncology Group malignant glioma
trials. J Natl Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeAngelis LM: Brain tumors. N Engl J Med.
344:114–123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nelson ER, Wardell SE, Jasper JS, Park S,
Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V,
et al: 27-Hydroxycholesterol links hypercholesterolemia and breast
cancer pathophysiology. Science. 342:1094–1098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Umetani M and Shaul PW:
27-Hydroxycholesterol: The first identified endogenous SERM. Trends
Endocrinol Metab. 22:130–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Umetani M, Domoto H, Gormley AK, Yuhanna
IS, Cummins CL, Javitt NB, Korach KS, Shaul PW and Mangelsdorf DJ:
27-Hydroxycholesterol is an endogenous SERM that inhibits the
cardiovascular effects of estrogen. Nat Med. 13:1185–1192. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Q, Ishikawa T, Sirianni R, Tang H,
McDonald JG, Yuhanna IS, Thompson B, Girard L, Mineo C, Brekken RA,
et al: 27-Hydroxycholesterol promotes cell-autonomous, ER-positive
breast cancer growth. Cell Rep. 5:637–645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vini R, Juberiya AM and Sreeja S: Evidence
of pomegranate methanolic extract in antagonizing the endogenous
SERM, 27-hydroxycholesterol. IUBMB Life. 68:116–121. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simmons ML, Lamborn KR, Takahashi M, Chen
P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, et
al: Analysis of complex relationships between age, p53, epidermal
growth factor receptor, and survival in glioblastoma patients.
Cancer Res. 61:1122–1128. 2001.PubMed/NCBI
|
|
10
|
Smith JS, Tachibana I, Passe SM, Huntley
BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW,
James CD, et al: PTEN mutation, EGFR amplification and outcome in
patients with anaplastic astrocytoma and glioblastoma multiforme. J
Natl Cancer Inst. 93:1246–1256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shaw E, Seiferheld W, Scott C, Coughlin C,
Leibel L, Curran W and Mehta M: Reexamining the radiation therapy
oncology group (RTOG) recursive partitioning analysis (RPA) for
glioblastoma multiforme (GBM) patients. Int J Radiat Oncol Biol
Phys. 57:S135–S136. 2003. View Article : Google Scholar
|
|
12
|
Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu
N, Fu Z and You Y: miR-125b is critical for the suppression of
human U251 glioma stem cell proliferation. Brain Res. 1312:120–126.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li
YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates
proliferation of breast cancer MCF-7 cells via a
p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li G, Wang R, Gao J, Deng K, Wei J and Wei
Y: RNA interference-mediated silencing of iASPP induces cell
proliferation inhibition and G0/G1 cell cycle arrest in U251 human
glioblastoma cells. Mol Cell Biochem. 350:193–200. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cortez MA, Ivan C, Valdecanas D, Wang X,
Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al:
PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 108(pii):
djv3032015.PubMed/NCBI
|
|
16
|
Andersson MK, Afshari MK, Andrén Y, Wick
MJ and Stenman G: Targeting the oncogenic transcriptional regulator
MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT
signaling. J Natl Cancer Inst. 1092017.
|
|
17
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu DL, Sookthai D, Le Cornet C, Katzke VA,
Johnson TS, Kaaks R and Fortner RT: Reproducibility of serum
oxysterols and lanosterol among postmenopausal women: Results from
EPIC-Heidelberg. Clin Biochem. 52:117–122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosner B: Fundamentals of Biostatistics.
Nelson Education. (Canada). 286–298. 2015.
|
|
20
|
Metz CE: Basic principles of ROC analysis.
Semin Nucl Med. 8:283–298. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zweig MH and Campbell G:
Receiver-operating characteristic (ROC) plots: A fundamental
evaluation tool in clinical medicine. Clin Chem. 39:561–577.
1993.PubMed/NCBI
|
|
22
|
Sherry MM, Reeves A, Wu JK and Cochran BH:
STAT3 is required for proliferation and maintenance of multipotency
in glioblastoma stem cells. Stem cells. 27:2383–2392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133(+) and CD133(−) glioblastoma-derived cancer stem cells
show differential growth characteristics and molecular profiles.
Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ye X and Weinberg RA:
Epithelial-mesenchymal plasticity: A central regulator of cancer
progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kahlert U, Nikkhah G and Maciaczyk J:
Epithelial-to-mesenchymal(-like) transition as a relevant molecular
event in malignant gliomas. Cancer Lett. 331:131–138. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vonlanthen S, Heighway J, Altermatt HJ,
Gugger M, Kappeler A, Borner MM, van Lohuizen M and Betticher DC:
The bmi-1 oncoprotein is differentially expressed in non-small cell
lung cancer and correlates with INK4A-ARF locus expression. Br J
Cancer. 84:1372–1376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu
LJ, Kong QL, Xu LH, Zhang X, Liu WL, et al: The polycomb group
protein Bmi-1 represses the tumor suppressor PTEN and induces
epithelial-mesenchymal transition in human nasopharyngeal
epithelial cells. J Clin Invest. 119:3626–3636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Elsaba TM, Martinez-Pomares L, Robins AR,
Crook S, Seth R, Jackson D, McCart A, Silver AR, Tomlinson IP and
Ilyas M: The stem cell marker CD133 associates with enhanced colony
formation and cell motility in colorectal cancer. PLoS One.
5:e107142010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu C and Shervington A: Chemoresistance in
gliomas. Mol Cell Biochem. 312:71–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bredel M: Anticancer drug resistance in
primary human brain tumors. Brain Res Brain Res Rev. 35:161–204.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bronger H, König J, Kopplow K, Steiner HH,
Ahmadi R, Herold-Mende C, Keppler D and Nies AT: ABCC drug efflux
pumps and organic anion uptake transporters in human gliomas and
the blood-tumor barrier. Cancer Res. 65:11419–11428. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reardon DA, Conrad CA, Cloughesy T, Prados
MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, et
al: Phase I study of AEE788, a novel multitarget inhibitor of ErbB-
and VEGF-receptor-family tyrosine kinases, in recurrent
glioblastoma patients. Cancer Chemother Pharmacol. 69:1507–1518.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Capes-Davis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR and Freshney RI: Check your cultures! A list of
cross-contaminated or misidentified cell lines. Int J Cancer.
127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cemeus C, Zhao TT, Barrett GM, Lorimer IA
and Dimitroulakos J: Lovastatin enhances gefitinib activity in
glioblastoma cells irrespective of EGFRvIII and PTEN status. J
Neurooncol. 90:9–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
